Neurocrine(NBIX) - 2024 Q4 - Annual Results

Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 INGREZZA (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and$2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively ® • INGREZZA fourth quarter and fiscal 2024 net product sales were $615 million and$2.3 billion, respectively • INGREZZA fourth quarter net product sales grew 23% compared to fourth quarter 2023, drive ...